Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids

Biomedicine and Pharmacotherapy

Volumn 66, Issue 4, 2012, Pages 300-307

  Fazzi, P ^a   Manni, E ^a   Cristofani, R ^a   Cei, G ^a   Piazza, S ^a   Calabrese, R ^a   Antonelli, A ^a   Siciliano, G ^a   Barachini, P ^a   Carpi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Lung impairment; Neuropathy; Skin sarcoidosis; Thalidomide

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLADDER TOXICITY; BLOOD TOXICITY; BRONCHUS HYPERREACTIVITY; CANCER RISK; CATARACT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CUSHING SYNDROME; CUTANEOUS CHRONIC SARCOIDOSIS; CUTANEOUS REFRACTORY SARCOIDOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; HIRSUTISM; HUMAN; HYPERCALCEMIA; HYPERTENSION; INFECTION; INFECTION RISK; KIDNEY DYSFUNCTION; LEG THROMBOSIS; LEUKOPENIA; LIVER TOXICITY; LUNG CAPACITY; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; MATHEMATICAL PARAMETERS; MYOCARDIAL REFRACTORY SARCOIDOSIS; OCULAR SARCOIDOSIS; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PLEURAL SARCOIDOSIS; PRIORITY JOURNAL; PULMONARY CHRONIC REFRACTORY SARCOIDOSIS; PULMONARY REFRACTORY SARCOIDOSIS; REFRACTORY NEUROSARCOIDOSIS; RENAL SARCOIDOSIS; RETINA TOXICITY; SARCOIDOSIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SKIN TEST; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; WEIGHT GAIN;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SARCOIDOSIS; SARCOIDOSIS, PULMONARY; SKIN DISEASES; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862489614     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.03.005     Document Type: Article

References (46)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
2. Crystal R.G., Roberts W.C., Hunninghake G.W., Gadek J.E., Fulmer J.D., Line B.R. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med 1981, 94:73-94.
3. Grutters J.C., van den Bosch J.M.M. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006, 28:627-636.
4. Paramothayan S., Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008, 102:1-9.
5. Wyser C.P., van Schalkwyk E.M., Alheit B., Bardin P.G., Joubert J.R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997, 156:1371-1376.
6. Londner C., Zendah I., Freynet O., Carton Z., Dion G., Nunes H., et al. Treatment of sarcoidosis. Rev Med Interne 2011, 32:109-113.
7. Denys B.G., Bogaerts Y., Coenegrachts K.L., De Vriese A.S. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?. Clin Sci 2007, 112:281-289.
8. Callejas-Rubio J.L., López-Pérez L., Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manage 2008, 4:1305-1313.
9. Laffitte E., Revuz J. Thalidomide. Ann Dermatol Venereol 2000, 127:603-613.
10. Tseng S., Pak G., Washenik K., Pomeranz M.K., Shupack J.L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996, 35:969-979.
11. Doherty S.D., Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008, 7:769-773.
12. Kontogiannis V., Powell R.J. Use of thalidomide in dermatological indications. BioDrugs 2000, 13:255-265.
13. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082-4085.
14. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812-817.
15. Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. Presse Med 1983, 12:963.
16. Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995, 32:866-869.
17. Lee J.B., Koblenzer P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998, 39:835-838.
18. Rousseau L., Beylot-Barry M., Doutre M.S., Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998, 134:1045-1046.
19. Estines O., Revuz J., Wolkenstein P., Bressieux J.M., Roujeau J.C., Cosnes A. Sarcoidosis: thalidomide treatment in ten patients. Ann Dermatol Venereol 2001, 128:611-613.
20. Oliver S.J., Kikuchi T., Krueger J.G., Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002, 102:225-236.
21. Baughman R.P., Judson M.A., Teirstein A.S., Moller D.R., Lower E.E. Thalidomide for chronic sarcoidosis. Chest 2002, 122:227-232.
22. Nguyen Y.T., Dupuy A., Cordoliani F., Vignon-Pennamen M.D., Lebbé C., Morel P., et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004, 50:235-241.
23. Judson M.A., Silvestri J., Hartung C., Byars T., Cox C.E. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:51-57.
24. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2003, 2:311-320.
25. Paoletti P., Pistelli G., Fazzi P., Viegi G., Di Pede F., Giuliano G., et al. Reference values for vital capacity and flow-volume curves from a general population study. Bull Eur Physiopathol Respir 1986, 22:451-459.
26. Blakemore W.S., Forster R.E., Morton J.W., Ogilvie C.M. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957, 36:1-17.
27. Molloy F.M., Floeter M.K., Syed N.A., Sandbrink F., Culcea E., Steinberg S.M., et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001, 24:1050-1057.
28. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
29. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., Flockhart D.A., et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997, 159:5157-5161.
30. Moller D.R., Forman J.D., Liu M.C., Noble P.W., Greenlee B.M., Vyas P., et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996, 156:4952-4960.
31. Jenkins S.C., Moxham J. The effects of mild obesity on lung function. Respir Med 1991, 85:309-311.
32. Jones R.L., Nzekwu M.M.U. The effects of body mass index on lung volumes. Chest 2006, 130:827-833.
33. Baughman R.P., Judson M.A., Teirstein A., Lower E.E., Lo K., Schlenker-Herceg R., et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008, 9:155-161.
34. Ye Q., Chen B., Tong Z., Nakamura S., Sarria R., Costabel U., et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006, 28:824-831.
35. Tabata C., Tabata R., Kadokawa Y., Hisamori S., Takahashi M., Mishima M., et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007, 179:708-714.
36. Choe J.Y., Jung H.J., Park K.Y., Kum Y.S., Song G.G., Hyun D.S., et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010, 59:177-188.
37. Urbauer E., Kaufmann H., Nösslinger T., Raderer M., Drach J. Thromboembolic events during treatment with thalidomide. Blood 2002, 99:4247-4248.
38. Wulff C.H., Høyer H., Asboe-Hansen G., Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985, 112:475-480.
39. Aronson I.K., Yu R., West D.P., Van den Broek H., Antel J. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 1984, 120:1466-1470.
40. Ochonisky S., Verroust J., Bastuji-Garin S., Gherardi R., Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994, 130:66-69.
41. Fullerton P.M., O'Sullivan D.J. Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatr 1968, 31:543-551.
42. Cavaletti G., Beronio A., Reni L., Ghiglione E., Schenone A., Briani C., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004, 62:2291-2293.
43. Florence A.L. Is thalidomide to blame?. BMJ 1960, 2:1954.
44. Fullerton P.M., Kremer M. Neuropathy after intake of thalidomide (distaval). Br Med J 1961, 2:855-858.
45. Chaudhry V., Cornblath D.R., Corse A., Freimer M., Simmons-O'Brien E., Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002, 59:1872-1875.
46. Johnson D.C., Corthals S.L., Walker B.A., Ross F.M., Gregory W.M., Dickens N.J., et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011, 29:797-804.